aTyr Pharma (ATYR) investor relations material

Executive summary

• Report covers the quarter ended June 30, 2026, for a clinical-stage biotech focused on tRNA synthetase biology for fibrosis and inflammation therapies.

• Lead candidate efzofitimod is in development for interstitial lung disease (ILD), with a new Phase 3 study planned after a prior study did not meet its primary endpoint.

• Announced a 60% workforce reduction and program prioritization to focus resources on efzofitimod in ILD, particularly pulmonary sarcoidosis and systemic sclerosis-related ILD.

• Awaiting FDA feedback by end of August 2026 on the protocol for a planned Phase 3 study of efzofitimod in pulmonary sarcoidosis.

• Enrollment completed in the Phase 2 EFZO-CONNECT study for efzofitimod in SSC-ILD; topline results expected Q1 2027.

Financial highlights

• Cash, cash equivalents, restricted cash, and available-for-sale investments totaled $58.9 million as of June 30, 2026.

• Net loss was $10.3 million for Q2 2026, compared to $19.5 million in Q2 2025.

• Research and development expenses were $6.7 million and general and administrative expenses were $4.1 million for Q2 2026.

• Research and development expenses decreased year-over-year due to completion of the EFZO-FIT study, while preclinical expenses increased for new candidates.

• No revenue from product sales; operations funded primarily through equity offerings.

Outlook and guidance

• Restructuring and cost-saving measures are expected to reduce annualized operating expenses by approximately $13 million starting Q4 2026.

• Existing cash is expected to fund operations for at least one year from the filing date, with some projections extending runway into late 2028.

• Additional capital will be required to conduct the planned Phase 3 study and future commercialization.

• General and administrative expenses are expected to decrease following the restructuring.

• Topline results from the Phase 2 EFZO-CONNECT study in SSC-ILD anticipated in Q1 2027.